Meta-analyses of early-stage hodgkin lymphoma

Acta Haematologica

Volumn 125, Issue 1-2, 2010, Pages 32-38

  Herbst, Christine ^a   Engert, Andreas ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

Chemoradiotherapy; Chemotherapy; Combined modality treatment; Early stage lymphoma; Hodgkin lymphoma; Radiotherapy

Indexed keywords

ARTICLE; CANCER RISK; CANCER STAGING; CHEMORADIOTHERAPY; EARLY CANCER; HODGKIN DISEASE; HUMAN; META ANALYSIS (TOPIC); PRIORITY JOURNAL; SECOND CANCER;

ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; HODGKIN DISEASE; HUMANS; META-ANALYSIS AS TOPIC; RADIOTHERAPY;

EID: 78650393395     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000318885     Document Type: Article

References (34)

1. Swerdlow AJ: Epidemiology of Hodgkin's disease and non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 2003; 30(suppl 1):S3-S12.
2. Thomas RK, Re D, Zander T, Wolf J, Diehl V: Epidemiology and etiology of Hodgkin's lymphoma. Ann Oncol 2002; 13(suppl 4):147-152.
3. DeVita VT Jr: MPHN: Hodgkin's Disease; Philadelphia, Lippincott-Raven, 1997, pp 2242-2283.
4. Glaser SL, Jarrett RF: The epidemiology of Hodgkin's disease. Baillières Clin Haematol 1996; 9: 401-416.
5. Engert A, Schiller P, Josting A, Herrmann R, Koch P, Sieber M, Boissevain F, De Wit M, Mezger J, Duhmke E, Willich N, Muller RP, Schmidt BF, Renner H, Muller-Hermelink HK, Pfistner B, Wolf J, Hasenclever D, Loffler M, Diehl V: Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early- stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2003; 21: 3601-3608.
6. Sasse S, Diehl V, Engert A: Combined modality treatment for early-stage Hodgkin's lymphoma: the GHSG experience. Haematol Rep 2006; 2: 19-22.
7. Noordijk EM, Thomas J, Fermé C, Noordijk EM, van't Veer MB, Brice P, Divine M, Morschhauser F, Carde P, Eghbali H, Henry- Amar M: First results of the EORTC-GELA H9 randomized trials: the H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkin's lymphoma (HL). J Clin Oncol 2005; 21(suppl 1):abstract 6506.
8. Aleman BM, van den Belt-Dusebout AW, Klokman WJ, Van't Veer MB, Bartelink H, van Leeuwen FE: Long-term cause-specific mortality of patients treated for Hodgkin's disease. J Clin Oncol 2003; 21: 3431-3439.
9. Franklin JG, Paus MD, Pluetschow A, Specht L: Chemotherapy, radiotherapy and combined modality for Hodgkin's disease, with emphasis on second cancer risk. Cochrane Database Syst Rev 2005; 4:CD003187.
10. Adams MJ, Lipsitz SR, Colan SD, Tarbell NJ, Treves ST, Diller L, Greenbaum N, Mauch P, Lipshultz SE: Cardiovascular status in longterm survivors of Hodgkin's disease treated with chest radiotherapy. J Clin Oncol 2004; 22: 3139-3148.
11. Behringer K, Breuer K, Reineke T, May M, Nogova L, Klimm B, Schmitz T, Wildt L, Diehl V, Engert A: Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2005; 23: 7555-7564.
12. Ng AK, Bernardo MV, Weller E, Backstrand K, Silver B, Marcus KC, Tarbell NJ, Stevenson MA, Friedberg JW, Mauch PM: Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. Blood 2002; 100: 1989-1996.
13. Dores GM, Metayer C, Curtis RE, Lynch CF, Clarke EA, Glimelius B, Storm H, Pukkala E, van Leeuwen FE, Holowaty EJ, Andersson M, Wiklund T, Joensuu T, Van't Veer MB, Stovall M, Gospodarowicz M, Travis LB: Second malignant neoplasms among longterm survivors of Hodgkin's disease: a population- based evaluation over 25 years. J Clin Oncol 2002; 20: 3484-3494.
14. Ng AK, Bernardo MP, Weller E, Backstrand KH, Silver B, Marcus KC, Tarbell NJ, Friedberg J, Canellos GP, Mauch PM: Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger. J Clin Oncol 2002; 20: 2101-2108.
15. Bhatia S, Yasui Y, Robison LL, Birch JM, Bogue MK, Diller L, DeLaat C, Fossati-Bellani F, Morgan E, Oberlin O, Reaman G, Ruymann FB, Tersak J, Meadows AT: High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin's disease: report from the Late Effects Study Group. J Clin Oncol 2003; 21: 4386-4394.
16. van Leeuwen FE, Klokman WJ, Veer MB, Hagenbeek A, Krol AD, Vetter UA, Schaapveld M, van Heerde P, Burgers JM, Somers R, Aleman BM: Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood. J Clin Oncol 2000; 18: 487-497.
17. Green DM, Hyland A, Barcos MP, Reynolds JA, Lee RJ, Hall BC, Zevon MA: Second malignant neoplasms after treatment for Hodgkin's disease in childhood or adolescence. J Clin Oncol 2000; 18: 1492-1499.
18. Canellos GP: Chemotherapy alone for early Hodgkin's lymphoma: an emerging option. J Clin Oncol 2005; 23: 4574-4576.
19. Meyer RM: Is there convincing evidence for the use of chemotherapy alone in patients with limited stage Hodgkin's lymphoma? Eur J Haematol 2005;(suppl):115-120.
20. Loeffler M, Brosteanu O, Hasenclever D, Sextro M, Assouline D, Bartolucci AA, Cassileth PA, Crowther D, Diehl V, Fisher RI, Hoppe RT, Jacobs P, Pater JL, Pavlovsky S, Thompson E, Wiernik P: Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International Database on Hodgkin's Disease Overview Study Group. J Clin Oncol 1998; 16: 818-829.
21. Specht L, Gray RG, Clarke MJ, Peto R: Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin's disease: a metaanalysis of 23 randomized trials involving 3,888 patients. International Hodgkin's Disease Collaborative Group. J Clin Oncol 1998; 16: 830-843.
22. Rehan FA, Bohlius J, Brillant C, Monsef I, Specht L, Engert A: Chemotherapy alone versus chemotherapy plus radiotherapy for early stage Hodgkin lymphoma (protocol). Cochrane Database Syst Rev 2008; 2: CD007110.
23. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M: Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 1971; 31: 1860-1861.
24. Lister TA, Crowther D, Sutcliffe SB, Glatstein E, Canellos GP, Young RC, Rosenberg SA, Coltman CA, Tubiana M: Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989; 7: 1630-1636.
25. Specht L, Nissen NI: Hodgkin's disease and age. Eur J Haematol 1989; 43: 127-135.
26. Shore T, Nelson N, Weinerman B. A metaanalysis of stages I and II Hodgkin's disease. Cancer 1990; 65: 1155-60.
27. Herbst C, Rehan FA, Brillant C, Bohlius J, Skoetz N, Schulz H, Monsef I, Specht L, Engert A: Combined modality treatment improves tumor control and overall survival in patients with early stage Hodgkin's lymphoma: a systematic review. Haematologica 2010; 95: 494-500.
28. Nachman JB, Sposto R, Herzog P, Gilchrist GS, Wolden SL, Thomson J, Kadin ME, Pattengale P, Davis PC, Hutchinson RJ, White K: Randomized comparison of low-dose involved- field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy. J Clin Oncol 2002; 20: 3765-3771.
29. Laskar S, Gupta T, Vimal S, Muckaden MA, Saikia TK, Pai SK, Naresh KN, Dinshaw KA: Consolidation radiation after complete remission in Hodgkin's disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a need? J Clin Oncol 2004; 22: 62-68.
30. Picardi M, De Renzo A, Pane F, Nicolai E, Pacelli R, Salvatore M, Rotoli B: Randomized comparison of consolidation radiation versus observation in bulky Hodgkin's lymphoma with post-chemotherapy negative positron emission tomography scans. Leuk Lymphoma 2007; 48: 1721-1727.
31. O'Dwyer PJ, Wiernik PH, Stewart MB, Slawson RG: Treatment of early stage Hodgkin's disease: a randomized controlled trial of radiotherapy plus chemotherapy versus chemotherapy alone; in Cavalli F, Bonadonna G, Rozencweig M (eds): Malignant Lymphomas and Hodgkin's Disease: Experimental and Therapeutic Advances. Proceedings of the Second International Conference on Malignant Lymphomas, Lugano, Switzerland, June 13-16, 1984. Dev Oncol. Berlin, Springer, 1985, vol 32, pp 329-336.
32. Meyer RM, Gospodarowicz MK, Connors JM, Pearcey RG, Bezjak A, Wells WA, Burns BF, Winter JN, Horning SJ, Dar AR, Djurfeldt MS, Ding K, Shepherd LE, National Cancer Institute of Canada Clinical Trials Group, Eastern Cooperative Oncology Group: Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol 2005; 23: 4634-4642.
33. Kung FH, Schwartz CL, Ferree CR, London WB, Ternberg JL, Behm FG, Wharam MD, Falletta JM, de Alarcon P, Chauvenet AR: POG 8625: a randomized trial comparing chemotherapy with chemoradiotherapy for children and adolescents with stages I, IIA, IIIA1 Hodgkin disease: a report from the Children's Oncology Group. J Pediatr Hematol Oncol 2006; 28: 362-368.
34. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V: Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579-586.